Robert Taub
Co-founder & Executive Chairman
Claimed by owner Nyxoah
Former names:
Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea
Public on Euronext Sep, 2020
Public on NASDAQ Jul, 2021
Public on NASDAQ Jul, 2021
Nyxoah
financialpost.com
•
Mar 23, 2023
Nyxoah Announces a $15 Million Private Placement Financing
www.globenewswire.com
•
Mar 6, 2023
Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
www.globenewswire.com
•
Aug 2, 2022
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test
www.globenewswire.com
•
Jul 18, 2022
Nyxoah Announces CE Mark Approval for Genio® 2.1
www.globenewswire.com
•
Jul 11, 2022
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients
www.globenewswire.com
•
Mar 24, 2022
Nyxoah Reports Full Year 2021 Operating and Financial Results
www.globenewswire.com
•
Jul 8, 2021
Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters' Full Exercise of Option to Purchase Additional Shares
www.globenewswire.com
•
Jan 26, 2021
Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)
www.globenewswire.com
•
Jan 5, 2021
First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)
en.globes.co.il
•
Sep 29, 2020
Sleep disorder co Nyxoah raises €85m in Euronext IPO
www.globenewswire.com
•
Sep 9, 2020
Nyxoah launches its Initial Public Offering on Euronext Brussels
www.globenewswire.com
•
Aug 27, 2020
Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brussels
www.sleepreviewmag.com
•
Jun 25, 2020
Nyxoah Gets FDA OK to Begin Study on Its Implanted Neurostimulator for Sleep Apnea
www.globenewswire.com
•
Feb 13, 2020
Nyxoah raises €25 million in private funding round
www.aumanufacturing.com.au
•
Feb 13, 2020
Cochlear ups investment in sleep device - Australian Manufacturing Forum
www.globenewswire.com
•
Oct 28, 2019
Nyxoah publishes positive Obstructive Sleep Apnea data from BLAST OSA study in the European Respiratory Journal
www.medicaldesignandoutsourcing.com
•
Mar 29, 2019
Nyxoah sleep apnea nerve-stim therapy gains CE Mark - Medical Design and Outsourcing
en.globes.co.il
•
Nov 12, 2018
Sleep disorder device co Nyxoah raises $17m
www.huffingtonpost.co.uk
•
Apr 4, 2017
This Tiny Implant Uses Electrical Impulses To Stop You Snoring
www.globes.co.il
•
Jul 5, 2016
Sleep apnea prevention co Nyxoah raises $20m
www.globes.co.il
•
May 21, 2014
Sleep Apnea co Nyxoah raises €8 million
About
Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA).
The company has developed a battery-free, leadless, minimally invasive neurostimulator capable of delivering bilateral hypoglossal nerve stimulation for patients with moderate to severe OSA who have failed at conventional positive airway pressure therapy.
Nyxoahs therapy consists of a tiny neurostimulator that is implanted in the chin area in a minimally invasive surgery. The system, which is powered by a miniature external battery, is placed under the chin and stimulates the tongue nerve.
In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for treatment of obstructive sleep apnea. In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for the current Genio neurostimulation-based OSA therapy for treatment of obstructive sleep apnea.
The company has developed a battery-free, leadless, minimally invasive neurostimulator capable of delivering bilateral hypoglossal nerve stimulation for patients with moderate to severe OSA who have failed at conventional positive airway pressure therapy.
Nyxoahs therapy consists of a tiny neurostimulator that is implanted in the chin area in a minimally invasive surgery. The system, which is powered by a miniature external battery, is placed under the chin and stimulates the tongue nerve.
In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for treatment of obstructive sleep apnea. In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for the current Genio neurostimulation-based OSA therapy for treatment of obstructive sleep apnea.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
Genio
Geographic markets
Global, Europe
Funding
Total Funding
$190.7M
Market Cap
$249.93M
Last Funding
$15M
Funding Stage
Total Rounds
7
Investors
8
News
(21)
financialpost.com
•
Mar 23, 2023
Nyxoah Announces a $15 Million Private Placement Financing
www.globenewswire.com
•
Mar 6, 2023
Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
www.globenewswire.com
•
Aug 2, 2022
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test
www.globenewswire.com
•
Jul 18, 2022
Nyxoah Announces CE Mark Approval for Genio® 2.1
www.globenewswire.com
•
Jul 11, 2022
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients
www.globenewswire.com
•
Mar 24, 2022
Nyxoah Reports Full Year 2021 Operating and Financial Results
www.globenewswire.com
•
Jul 8, 2021
Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters' Full Exercise of Option to Purchase Additional Shares
www.globenewswire.com
•
Jan 26, 2021
Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)
www.globenewswire.com
•
Jan 5, 2021
First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)
en.globes.co.il
•
Sep 29, 2020
Sleep disorder co Nyxoah raises €85m in Euronext IPO
www.globenewswire.com
•
Sep 9, 2020
Nyxoah launches its Initial Public Offering on Euronext Brussels
www.globenewswire.com
•
Aug 27, 2020
Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brussels
www.sleepreviewmag.com
•
Jun 25, 2020
Nyxoah Gets FDA OK to Begin Study on Its Implanted Neurostimulator for Sleep Apnea
www.globenewswire.com
•
Feb 13, 2020
Nyxoah raises €25 million in private funding round
www.aumanufacturing.com.au
•
Feb 13, 2020
Cochlear ups investment in sleep device - Australian Manufacturing Forum
www.globenewswire.com
•
Oct 28, 2019
Nyxoah publishes positive Obstructive Sleep Apnea data from BLAST OSA study in the European Respiratory Journal
www.medicaldesignandoutsourcing.com
•
Mar 29, 2019
Nyxoah sleep apnea nerve-stim therapy gains CE Mark - Medical Design and Outsourcing
en.globes.co.il
•
Nov 12, 2018
Sleep disorder device co Nyxoah raises $17m
www.huffingtonpost.co.uk
•
Apr 4, 2017
This Tiny Implant Uses Electrical Impulses To Stop You Snoring
www.globes.co.il
•
Jul 5, 2016
Sleep apnea prevention co Nyxoah raises $20m
www.globes.co.il
•
May 21, 2014
Sleep Apnea co Nyxoah raises €8 million
The Team
(5)
RT
OT
Olivier Taelman
CEO
AM
Adi Mashiach
Founder & Former CEO
DN
Dorit Nahari
Vice President Operations
NG
Nathalie Gilat
General Manager Israel
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$100M
Sep 2020
Stock Exchange
Euronext
Valuation
$423M
$100M
Public Offering
Undisclosed
Jul 2021
Stock Exchange
NASDAQ
Valuation
Undisclosed
Undisclosed
Private Equity Funding
A Round
$11M
May 2014
3 Investors
$11M
B Round
$20M
Jul 2016
4 Investors
$20M
B Round
$17.1M
Nov 2018
1 Investors
$17.1M
Undisclosed Round
$27.6M
Feb 2020
2 Investors
$27.6M
Post-IPO Equity Funding
$15M
Mar 2023
$15M
Media gallery
(2)
Locations
Israel
Yigal Alon Street 126, Tel Aviv-Yafo, Israel
Offices Abroad
Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium
Locations
Israel
Yigal Alon Street 126, Tel Aviv-Yafo, Israel
Offices Abroad
Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,